The whole cheat sheet, one page.

50 mg orally daily, sometimes 100 to 150 mg split, in roughly 8-week cycles. No established human dose.

No established human dose. Typically 0.05% in topical serum applied to scalp once or twice daily, leave-in. No injection protocol exists.

250 to 500 mcg SubQ once daily, commonly in the morning. Some protocols cycle 5 days on, 2 off.

4 mg SubQ once daily. Trial courses ran 28 days. Gray-market use copies this pattern.

250 to 500 mcg SubQ once or twice daily near injury site, in 4 to 12 week cycles. 500 mcg to 1 mg orally for gut goals.

Start 0.25 mg SubQ once weekly, titrate stepwise every 4 weeks to 2.4 mg/week. Common gray-market reconstitution: 5 mg vial in 2 mL bacteriostatic water.

100 to 200 mcg SubQ daily for 10 to 20 consecutive days, repeated quarterly. No validated human dose exists. Wide inconsistency across vendor sources.

5 to 10 mL IM daily for 10 to 20 days (community); clinical trials used 30 mL IV over 15 to 60 minutes in saline. No community oral route exists.

100 mcg SubQ per injection, 1 to 3 times daily in fasted windows. Almost always stacked with ipamorelin. No validated human dose for the no-DAC form.

5 to 30 mg orally or sublingually per day (community only). No human clinical dose exists. Foundational mechanism papers retracted 2025.

100 to 500 mcg SubQ 30 to 60 minutes before bed. Original human trials used IV infusion at 25 nmol per kg. No validated SubQ dose.

5 to 10 mg SubQ daily for 10 to 20 consecutive days, once or twice per year. No validated human dose.

1 to 2 mg SubQ daily to several times weekly (injectable, where legal). Topical: 1 to 3% serum daily, well-supported route.

100 to 300 mcg SubQ, 2 to 3x daily, fasted. Pre-workout and pre-bed windows most common.

100 mcg SubQ, 1 to 3x daily, fasted. Up to 300 mcg per injection in some protocols. Often paired with a GHRH analog.

100 to 200 mcg SubQ, 1 to 3x daily, fasted. Often cycled 5 days on, 2 days off to slow tachyphylaxis.

200 to 300 mcg SubQ, 1 to 3x daily, fasted, pre-bed dose prioritized. Almost always paired with CJC-1295.

100 to 200 mcg SubQ once daily (wellness community report, KP-10). Clinical trials used kisspeptin-54 at much higher supervised doses. No established human wellness protocol.

250 to 500 mcg SubQ or oral daily, cycles of 4 to 8 weeks, no human trial dose established

100 to 300 mcg SubQ daily, 5 days on, 4 to 6 week course, titrate from 100 mcg. No controlled human SubQ trial exists.

FDA-approved: 16 mg implant every 2 months by provider. Gray-market injectable: 0.5 to 1 mg SubQ daily loading, no validated protocol.

0.25 to 0.5 mg SubQ daily or every other day during loading, then 0.25 mg maintenance 1 to 2x weekly. Start low to blunt nausea.

10 to 25 mg oral once daily, typically at night before sleep. Not injected, no reconstitution required.

5 to 10 mg SubQ, 3 to 5x per week. No established clinical dose. First human trial ongoing as of 2026.

IV: 250 to 750 mg infused over 1 to 4+ hours, slow rate required. SubQ: 20 to 100 mg, 2 to 3x per week. IM: 50 to 200 mg, 1 to 3x per week. No established optimal protocol.

250 to 500 mcg SubQ once daily in 10 to 20 day cycles. No validated human dose exists.

5 to 10 mg SubQ once daily in short cycles of 10 days, reported not prescribed. No established human protocol.

1.75 mg SubQ (approved Vyleesi dose) 45 minutes before activity, max 1 dose per 24 hours and 8 per month. Gray-market protocols often report 1 to 2 mg.

2 mg SubQ once weekly to start, titrated monthly toward 4 to 12 mg maintenance. Reported not prescribed. Slow titration required to manage GI effects.

250 to 300 mcg intranasally, 1 to 3x daily in short cycles. SubQ reported but less common. No FDA-approved dose.

0.25 mg SubQ weekly (starter), titrate over 16 weeks to 2.4 mg weekly maintenance (Wegovy label). Compounded vials vary, verify mg/mL before drawing.

200 to 600 mcg intranasally daily, divided AM and midday. SubQ protocols also reported at similar microgram ranges.

200 to 500 mcg SubQ nightly, fasted, timed to natural GH pulse before sleep.

3 to 10 percent w/w in finished serum or cream, applied twice daily to expression-line zones. Not injected.

Community 3 to 5 mg SubQ daily, or about 4 mg SubQ 3x per week (~12 mg/week). The approved drug FORZINITY (elamipretide, FDA 2025 for Barth syndrome) is 40 mg SubQ once daily. Community dose is far lower.

2.4 to 4.8 mg SubQ once weekly, titrated stepwise every 2 to 4 weeks from 0.6 mg. Trial sweet spot was 4.8 mg. No approved consumer protocol exists.

750 mcg to 2 mg SubQ twice weekly for 4 to 6 weeks loading, then 750 mcg to 1 mg twice monthly maintenance

2 mg SubQ once daily (Egrifta) or 1.28 mg SubQ once daily (EGRIFTA WR room-temp formulation), prescription only

1.6 mg SubQ twice weekly, clinical regimen for hepatitis, community protocols mirror this

2 mg SubQ daily for 20 days, cycled 2 to 3 times per year, no validated human dose exists

2.5 mg SubQ once weekly titrating up to 5, 10, or 15 mg once weekly, FDA-approved prescription label

50 mcg per metered intranasal spray, up to 4 sprays per day, no established SubQ human dose